Your mindset matters — now more than ever.
We are in the midst of a drug epidemic.
The drug? Negative news. The drug pushers? The media.
As I wrote in Abundance: The Future Is Better Than You Think, we pay 10x more attention to negative news than positive news.
We are being barraged with negative news on every device. This constant onslaught distorts your perspective on the future and inhibits your ability to make a positive impact.
Recorded Oct 4th, 2017
Link to the interview, goo.gl/8rQ6YS
Link to Aubrey de Grey’s SENS Research Foundation — http://www.sens.org/
I join this 30 min panel with scientists and a mother with a down syndrome child on Turkish national television to debate genetic editing. I adovcate for allowing genetic editing to improve the human race, despite fears:
Better, stronger, disease-free humans. Editing human DNA could save lives and enhance them. But should we be playing god?
Genes determine our health, looks, the way we function. They’re the ingredients for life. The idea that we could one day change them is an exciting prospect, but also an ethical minefield. As science moves closer towards gene editing, the concern is that it could go too far and even create a new elite group of enhanced humans.
Subscribe: http://trt.world/subscribe
A treatment that can stop patients from going blind is poised to be the first gene therapy for an inherited condition approved in the U.S., in what would be a major scientific milestone — and also open the door for record-breaking drug prices and novel ways to pay for them.
Spark Therapeutics Inc.’s Luxturna therapy crossed a key hurdle Thursday when it won backing from a group of advisers to the U.S. Food and Drug Administration. After discussing the trial design, treatment procedure and safety profile, the panel of 16 experts voted unanimously that the drug’s benefits outweighed its risks.
We are doing a series of articles that discuss the Hallmarks of Aging. Published in 2013, this paper is highly regarded in academia and is one of the most cited papers in biology, with an average of being cited once every two days. The paper divides aging into distinct categories (“hallmarks”) of damage to explain how the aging process works and how it causes age-related diseases[1].
Today, we will be looking at one of the primary hallmarks, genomic instability.
Recorded Oct 4th, 2017
Link to the interview, goo.gl/8rQ6YS
Link to Aubrey de Grey’s SENS Research Foundation — http://www.sens.org/
The work, published in the March 8 issue of Science, finally proves that a single anti-aging enzyme in the body can be targeted, with the potential to prevent age-related diseases and extend lifespans.
The paper shows all of the 117 drugs tested work on the single enzyme through a common mechanism. This means that a whole new class of anti-aging drugs is now viable, which could ultimately prevent cancer, Alzheimer’s disease and type 2 diabetes.
“Ultimately, these drugs would treat one disease, but unlike drugs of today, they would prevent 20 others,” says the lead author of the paper, Professor David Sinclair, from UNSW Medicine, who is based at Harvard University. “In effect, they would slow aging.”
